Physician profile
John Shen
NPI 1437137866
$6,776.60
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $695 · 2021: $1,384 · 2022: $1,666 · 2023: $1,670 · 2024: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.27 |
| Education | $367.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,094.38 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,256.04 | 2019-2024 | Qulipta, Ubrelvy, Lo Loestrin Fe |
| Astellas Pharma US INC | $484.55 | 2019-2024 | Veozah, Myrbetriq |
| Currax Pharmaceuticals LLC | $422.84 | 2022-2024 | Contrave, Nexletol, Nexlizet |
| Pfizer INC. | $365.57 | 2019-2024 | |
| Exact Sciences Corporation | $312.25 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $241.81 | 2020-2023 | Injectafer |
| Mylan Pharmaceuticals INC. | $193.86 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $190.49 | 2022 | |
| Lilly USA, LLC | $181.09 | 2019-2024 | Zepbound, Jardiance |
| Avion Pharmaceuticals | $146.88 | 2020-2023 | Balcoltra |
| Mission Pharmacal Company | $128.57 | 2019-2023 | Citranatal |
| Exeltis, USA INC. | $113.84 | 2020-2023 | Slynd |
| Janssen Biotech, INC. | $85.85 | 2024 | Erleada |
| Therapeuticsmd, INC. | $85.03 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $79.48 | 2021-2024 | Nexplanon |
| Allergan, INC. | $78.17 | 2019-2021 | |
| Shield Therapeutics INC | $53.58 | 2023-2024 | Accrufer |
| Amag Pharmaceuticals, INC. | $48.49 | 2019 | |
| Evofem Biosciences, INC. | $39.18 | 2021 | |
| Myovant Sciences INC. | $33.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.09 | 2020-2021 | |
| Vivus LLC | $31.76 | 2022 | |
| Hologic Sales and Service, LLC | $21.19 | 2019 | |
| Lupin INC. | $16.05 | 2019 | |
| Mayne Pharma Commercial LLC | $14.82 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.22 | 2021 | |
| Eisai INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.